Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.

Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocr Rev. 2002 Aug;23(4):517-23. Review.

PMID:
12202466
2.

Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD, Guyatt G.

Cochrane Database Syst Rev. 2003;(4):CD004523. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD004523.

PMID:
14584020
3.

WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Adachi JD, Guyatt G, Papaioannou A, Robinson VA, Shea BJ, Tugwell P, Waldegger LM, Weaver B, Wells G, Zytaruk N.

Cochrane Database Syst Rev. 2007 Jul 18;(1):CD004523. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD004523.

PMID:
17636764
4.

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocr Rev. 2002 Aug;23(4):508-16. Review.

PMID:
12202465
5.

Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis.

Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocr Rev. 2002 Aug;23(4):540-51. Review.

PMID:
12202469
6.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.

JAMA. 1999 Oct 13;282(14):1344-52.

PMID:
10527181
7.
8.

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis.

Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, Shea B, Tugwell P, Wells G; Osteoporosis Research Advisory Group (ORAG).

Osteoporos Int. 2001;12(2):140-51.

PMID:
11303715
9.

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocr Rev. 2002 Aug;23(4):524-8. Review.

PMID:
12202467
10.

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.

Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S.

Calcif Tissue Int. 2004 Feb;74(2):129-35. Epub 2003 Dec 5.

PMID:
14648009
11.

Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.

Seibel MJ, Naganathan V, Barton I, Grauer A.

J Bone Miner Res. 2004 Feb;19(2):323-9. Epub 2003 Dec 16.

12.

Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.

Palomba S, Manguso F, Orio F Jr, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P.

Menopause. 2008 Jul-Aug;15(4 Pt 1):730-6. doi: 10.1097/gme.0b013e318159f190.

PMID:
18698280
13.

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004523. doi: 10.1002/14651858.CD004523.pub3. Review.

PMID:
18254053
14.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD005326.

PMID:
16856092
15.

Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.

Boonen S, Klemes AB, Zhou X, Lindsay R.

J Am Geriatr Soc. 2010 Apr;58(4):658-63. doi: 10.1111/j.1532-5415.2010.02763.x. Epub 2010 Mar 22.

PMID:
20345865
16.

Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women.

Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocr Rev. 2002 Aug;23(4):560-9. Review.

PMID:
12202471
17.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
18.

Etidronate for treating and preventing postmenopausal osteoporosis.

Cranney A, Welch V, Adachi JD, Guyatt G, Krolicki N, Griffith L, Shea B, Tugwell P, Wells G.

Cochrane Database Syst Rev. 2001;(4):CD003376. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD003376. Cochrane Database Syst Rev. 2008;(1):CD003376.

PMID:
11687195
19.

Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women.

Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocr Rev. 2002 Aug;23(4):529-39. Review.

PMID:
12202468
20.

Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis.

Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, Ortiz Z, Peterson J, Adachi J, Tugwell P, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocr Rev. 2002 Aug;23(4):552-9. Review.

PMID:
12202470

Supplemental Content

Support Center